Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

CBRE Group Insiders Sold US$3.3m Of Shares Suggesting Hesitancy

View original at finance.yahoo.com
CBRE Group Insiders Sold US$3.3m Of Shares Suggesting Hesitancy In the last year, many CBRE Group, Inc. (NYSE:CBRE) insiders sold a substantial stake in the company which may have sparked shareholders' attention…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We usually like to see fairly high levels of insider ownership

    60% confidence
  • Significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders

    60% confidence
  • We would consider it foolish to ignore insider transactions altogether

    60% confidence
  • Significant insider selling over the last three months makes us a bit cautious, but it's not the be all and end all

    60% confidence
  • The big sale took place at around the current price, so it's not too bad (but it's still not a positive)

    60% confidence
  • AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early

    60% confidence
  • We generally don't like to see insider selling, but the lower the sale price, the more it concerns us

    60% confidence
  • When multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag

    60% confidence
  • When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
CBRE Group Insiders Sold US$3.3m Of Shares Suggesting Hesitancy — Source | Via News | Finance Via News